Further studies with ILB® performed in human cells in vitro, in the rodent brain after sTBI, and in healthy humans and people with amyotrophic lateral sclerosis describe the remarkable anti-inflammatory activity of the drug, exploited through the biomodulation of different cytokines (e.g., TNF-α, IL-6 and TGF-β family) and growth factors (e.g., HGF, BDNF, VEGF) [57]. The gene discussed is VEGFA; the disease is amyotrophic lateral sclerosis.